JOAO ALBERTO OSSO JUNIOR

JOAO ALBERTO OSSO JUNIOR

(Fonte: Lattes)

ORCID

ScopusID

Resumo

Possui graduação em Química pela Universidade de São Paulo (1978), mestrado em Engenharia Nuclear pela Universidade Federal do Rio de Janeiro (1982) e doutorado em Ph D em Química Nuclear - University of Manchester (1986). Atualmente é pesquisador da Comissão Nacional de Energia Nuclear, revisor dos journals - Brazilian Archives of Biology and Technology, - Applied Radiation and Isotopes e professor pós-graduação da Universidade de São Paulo. Tem experiência na área de Engenharia Nuclear, com ênfase em Produção de Radioisótopos, atuando principalmente nos seguintes temas: medicina nuclear, tecnecio-99m, gerador tipo gel, reator nuclear e ciclotron. (Texto extraído do Currículo Lattes em 8 maio 2023)

Página do item completo

Resultados de Busca

Agora exibindo 1 - 10 de 120

Production of 57Co, 109Cd, 111In and 117mSn using CV-28 cyclotron at IPEN-CNEN/SP
2001 - OSSO JUNIOR, J.A.; LANDINI, L.; LION, L.F.; MORAES, V.
Several radioisotopes produced in Cyclotrons have physical properties of decay suitable to be used as: radiopharmaceuticals, for in vivo Diagnosis images (with the techniques of SPET and PET, Single Photon Emission Tomography and Positron Emission Tomography, respectively) and for Therapy, in Nuclear Medicine; calibration sources of several instruments applied in the nuclear area and in Metrology; and as radioactive tracers of elements investigated in many fields, such as Chemistry, Physics and Biology. This work describes the production of four of these radioisotopes that are very important in these areas: 57Co, 109Cd, 111ln and 117mSn. They can be obtained using the CV-28 Cyclotron at IPEN, because it can accelerate proton beams with energies up to 24MeV and currents up to 20μA (external). 57Co (t1/2=271.3 d) decays by electron capture to 57Fe with the emission of γ-rays and one characteristic X-ray. It is widely used as calibration source of detectors such as: Ge(Li), Ge(HP), Nal(TI) and dose calibrators (well type detectors). Besides these applications, 57Co Flood Sources are used to test the response uniformity of gamma cameras, in Nuclear Medicine. 109Cd has a half-life of 462.6 d and decays by electron capture to 109Ag with the emission of one γ-ray and one characteristic X-ray. This radioisotope can be employed as calibration source of X-ray and γ-rays detectors; as a radioactive tracer of Cd, an environment pollutant and used in the EDXRF (Energy Dispersion X-Ray Fluorescence) technique. 57Co was produced through the irradiation of natNi. Thick target yields for 55Co, 56Co, 57Co, 58CO, 56Ni and 57Ni were measured and the mean values were 346.69kBq/μA.h (9.37μCi/μA.h), for the direct production of 57Co and 150.59kBq/μA.h (4.07μCi/μA.h), through the decay of 57Ni (11.31 days after EOB - End of Bombardment). A solution of 57CoCl2 was prepared, to fill a flood source for calibration of gamma camera, with activity of 222MBq (6mCi) of 57Co and impurity levels of 1.13 and 1.29% for 56Co and 58Co, respectively, at delivery time. In order to achieve these results, a chemical separation method was developed with a separation yield of 93% for 5'7Co and a negligible loss of Ni. A composite target of Ni and Ag was prepared and a chemical separation method proposed to allow the separation between the targets and the products of interest, 57Co and 109Cd. The yields obtained in the irradiation of the composite target were: 947.94kBq/μA.h (25.62μCi/μA.h) of 57Co - direct reaction, 259-00kBq/μA.h (7μCi/μA.h) of 57Co - indirect reaction (11.31 days after EOB) and 71.41kBq/μA.h (1.93μCi/μA.h) of 109Cd, which showed the efficiency of its use, as well as the chemical separation, with a yield of 80% for 57Co and 109Cd. 111ln (t1/2=67.5 h) has appropriate characteristics for Diagnosis in Nuclear Medicine due to its decay mode (100% by electron capture) and its adequate half-life to slow biological studies, that makes it one of radioisotopes of interest of Brazilian Physicians. It can also be used in angular correlation studies in Nuclear Physics. 111In was produced by the 112Cd(p,2n)111ln reaction, that has the highest yield. The Cd targets were prepared by electroplating of CdSO4 solution in copper and copper/nickel backings. After being irradiated, a chemical separation was performed by an acetic acid extraction method, with an overall recovery yield for 111ln higher than 95%. The level of the chemical impurities of Cd, Ni and Cu were bellow than the permissible values. 117mSn (t1/2=14 d) has suitable characteristics of decay to be used as a tracer of SnCl2 in the labeling of organic molecules with 99mTc and also in radiotherapeutical applications. It was prepared by the irradiation of natural tin through the nuclear reactions natSn(p,xn)117Sb→117mSn. The production thick target yield of 117mSnnn was 784.4kBq/μA.h (21.20μCi/μA.h) and with the proper decay time of its precursor, 117Sb, no radionuclidic impurities appeared in the final product. A chemical separation method was developed to separate first 117Sb from the irradiated Tin and then 117mSn from Sb with a good chemical yield. The quality control procedures showed the good quality of the final product, 117mSn.
Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
2019 - BORBOREMA, SAMANTA E.T.; OSSO JUNIOR, JOAO A.; ANDRADE JUNIOR, HEITOR F. de; NASCIMENTO, NANCI do
Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by the protozoan Leishmania spp. Pentavalent antimonial agents have been used as an effective therapy, despite their side effects and resistant cases. Their pharmacokinetics remain largely unexplored. This study aimed to investigate the pharmacokinetic profile of meglumine antimoniate in a murine model of cutaneous leishmaniasis using a radiotracer approach. Methods: Meglumine antimoniate was neutron-irradiated inside a nuclear reactor and was administered once intraperitoneally to uninfected and L. amazonensis-infected BALB/c mice. Different organs and tissues were collected and the total antimony was measured. Results: Higher antimony levels were found in infected than uninfected footpad (0.29% IA vs. 0.14% IA, p = 0.0057) and maintained the concentration. The animals accumulated and retained antimony in the liver, which cleared slowly. The kidney and intestinal uptake data support the hypothesis that antimony has two elimination pathways, first through renal excretion, followed by biliary excretion. Both processes demonstrated a biphasic elimination profile classified as fast and slow. In the blood, antimony followed a biexponential open model. Infected mice showed a lower maximum concentration (6.2% IA/mL vs. 11.8% IA/mL, p = 0.0001), a 2.5-fold smaller area under the curve, a 2.7-fold reduction in the mean residence time, and a 2.5-fold higher clearance rate when compared to the uninfected mice. Conclusions: neutron-irradiated meglumine antimoniate concentrates in infected footpad, while the infection affects antimony pharmacokinetics.
Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model
2018 - BORBOREMA, SAMANTA E.T.; OSSO JUNIOR, JOAO A.; TEMPONE, ANDRE G.; ANDRADE JUNIOR, HEITOR F. de; NASCIMENTO, NANCI do
Visceral leishmaniasis (VL) is a fatal parasitic disease caused by the protozoan Leishmania spp. Meglumine antimoniate (MA) is the main treatment and has demonstrated a promising efficacy in a VL-model when encapsulated into negatively charged liposomes. Considering the current concept for the evaluation of pharmacokinetic parameters at early phases of drug discovery, we developed a formulation of MA-encapsulated into phosphatidylserine liposomes (MA-LP) and analyzed the in vitro antileishmanial activity, physicochemical properties, and pharmacokinetic profile in a mice model. The liposomal formulation had an internal mean diameter of 114 nm and a high stability in plasma. MA-LP was 23-fold more in vitro effective against Leishmania infantum-infected macrophages than the free drug, with a selectivity index higher than 220. The pharmacokinetic studies demonstrated that the liposomes increased the uptake of the drug by the liver and spleen and promoted sustained levels. MA-LP was first eliminated through renal excretion, followed by biliary excretion. In the blood, MA-LP followed a biexponential open model. This work emphasizes the importance of liposomes as potential drug delivery systems for visceral leishmaniasis.
Compartmental and dosimetric studies of anti-CD20 labeled with sup(188)Re
2016 - KURAMOTO, GRACIELA BARRIO; MATSUDA, MARGARETH M.N.; OSSO JUNIOR, JOAO A.
Radioimmunotherapy has the potential to deliver lethal radiation energy directly to malignant cells via targeting of radioisotope-conjugated monoclonal antibodies (MAbs) to specific antigens. Rituximab (RTX) is specifically targeted against CD20, a surface antigen expressed by B-lymphocytes. The use of 188Re from a 188W/188Re generator system represents an alternative radionuclide for therapy. Rhenium has chemical properties similar to technetium and both can be conjugated to antibodies using similar chemistry methods. The objective of this work is to prove the usefulness of this radiopharmaceutical based on dosimetric and pharmacokinetic studies that are also required by the Brazilian Regulatory Agency.
Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
2016 - BORBOREMA, SAMANTA E.T.; OSSO JUNIOR, JOAO A.; ANDRADE JUNIOR, HEITOR F. de; NASCIMENTO, NANCI do
Estudo de métodos de controle de qualidade do 99Mo utilizado em geradores 99Mo/99mTc produzidos no IPEN-CNEN/SP
2015 - SAID, D.S.; BRAMBILLA, T.P.; MATSUDA, M.M.N.; OSSO JUNIOR, J.A.
Desenvolvimento de geradores de sup(90)Sr-sup(90)Y
2007 - BARRIO, GRACIELA; OSSO JUNIOR, JOAO A.
Status report on thechnical progress for LEU-based sup(99)Mo production at IPEN-CNEN/SP, Brazil - Modified Cintichem process
2015 - OSSO JUNIOR, J.A.; DIAS, C.R.B.R.; TEODORO, R.; CATANOSO, M.F.; BRAMBILLA, T.P.; POZZO, L.; SQUAIR, P.; FUKUMORI, N.; CARVALHO, F.M.S.; ZINI, J.; CAMILO, R.L.; FORBICINI, C.; YAMAMURA, M.; ARAUJO, I.C.; FREITAS, A.A.; CARVALHO, E.U.; DURAZZO, M.; SILVA, A.M.; PIRES, M.A.; MARUMO, J.T.; DELLAMANO, J.C.; MENGATTI, J.; PERROTTA, J.A.
Otimização do metodo de preparo do radiofármaco sup(188)Re(V)DMSA
2012 - FELIX, THAIS A.; OSSO JUNIOR, JOAO A.
Development of biomolecules labelled with sup(177)Lu for cancer therapy
2006 - ARAUJO, ELAINE B. de; MENGATTI, JAIR; BARBOZA, MARYCEL F. de; COLTURATO, MARIA T.; OSSO JUNIOR, JOAO A.; CALDEIRA FILHO, JOSE de S.; HERRERIAS, ROSANA; MURAMOTO, EMIKO